Microphthalmia transcription factor: A sensitive and specific melanocyte marker for melanoma diagnosis

American Journal of Pathology

Volumn 155, Issue 3, 1999, Pages 731-738

  King, Roy ^a   Weilbaecher, Katherine N ^b   McGill, Gaël ^b   Cooley, Edward ^a   Mihm, Martin ^a,c   Fisher, David E ^b,d  

^a ALBANY MEDICAL CENTER   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; STEM CELL FACTOR; TRANSCRIPTION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

EID: 0032886830     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65172-3     Document Type: Article

References (48)

1. Silver WK: The Coat Colors of Mice: A Model for Mammalian Gene Action and Interaction. New York, Spinger-Verlag, 1979
2. Hughes AE. Newton VE, Liu XZ, Read AP: A gene for Waardenburg syndrome type 2 maps close to the human homologue of the microphthalmia gene at chromosome 3p12-p14.1. Nat Genet 1994, 7:509-512
3. Tassabehji M. Newton VE, Read AP: Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (MITF) gene. Nat Genet 1994, 8:251-255
4. Hodgkinson CA, Moore KJ, Nakayama A, Steingrimsson E, Copeland NG, Jenkins NA, Arheim H: Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 1993, 74:395-404
5. Hemesath TJ, Steingrimsson E, McGill G, Hansen MJ, Vaught J, Hodgkinson CA, Armheiter H, Copeland NG, Jenkins NA, Fisher DE: Microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev 1994, 8:2770-2780
6. Yasumoto K, Yokoyama K, Shibata K, Tomita Y, Shibahara S: Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene. Mol Cell Biol 1994, 14:8058-8070
7. Bentley NJ, Eisen T, Goding CR: Melanocyte-specific expression of the human tyrosinase promoter: activation by the microphthalmia gene product and role of the initiator. Mol Cell Biol 1994, 14:7996-8006
8. Bertolotto C, Abbe P, Hemesath TJ, Billek, Fisher DE, Ortonne JP, Ballotti R: Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J Cell Biol 1998, 142: 827-835
9. Price ER, Horstmann MA, Wells A, Weilbaecher K, Takemoto C, Landis M, Fisher D: αMSH signaling regulates expression of microphthalmia, a gene deficient in Waardenburg Syndrome. J Biol Chem 1998, 273:33042-33047
10. Lerner AB, Shibahara T, Boissy RE, Jacobson KA, Lamoreux ML, Moellmann GE: A mouse model for vitiligo. J Invest Dermatol 1986, 87:299-304
11. Steingrimsson E, Moore KJ, Lamoreux ML, Ferre D, Burley S, Zimring D, Skow L, Hodkinson C, Arnheiter H, Copeland N, Jenkins N: Molecular basis of mouse microphthalmia (mi) mutations helps explain their developmental and phenotypic consequences. Nat Genet 1994, 8:256-263
12. Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE: MAP kinase links the transcription factor microphthalmia to c-Kit signalling in melanocytes. Nature 1998, 391:298-301
13. Price ER, Ding H-F, Badalian T, Bhattacharya S, Takemoto C, Yao T, Hemesath T, Fisher D: Lineage-specific signaling in melanocytes. J Biol Chem 1998: 273:17983-17986
14. Sato S, Roberts K, Gambino G, Cook A, Kouzarides T, Goding CR: CBP/p300 as a co-factor for the microphthalmia transcription factor. Oncogene 1997; 14:3083-3092
15. Halaban R, Bohm M, Dotto P, Moellmann G, Cheng E, Zhang Y: Growth regulatory proteins that repress differentiation markers in melanocytes also downregulate the transcription factor microphthalmia. J Invest Dermatol 1996, 106:1266-1272
16. Barth A, Wanek LA, Morton DL: Prognostic factors in 1,512 melanoma patients with distant metastases. J Am Coll Surg 1995, 181:193-201
17. Evans GRD, Manson PN: Review and current perspectives of cutaneous malignant melanoma. J Am Coll Surg 1994, 178:523-540
18. DeVita V, Hellman S, Rosenberg S: Cancer: Principles and Practice of Oncolgoy. Vol. 2. Philadelphia, JB Lippincott Company, 1993, pp 2072-2092
19. Chang P, Knapper W: Metastatic melanoma of unknown primary. Cancer 1982, 49:1106-1111
20. Jonk A, Kroon B, Rumke P, Mooi W, Hart A, Van Dongen J: Lymph node metastasis from melanoma with an unknown primary site. Br J Surg 1990, 77:665-668
21. Reintgen D, McCarty K, Woodard B, Cox E, Seigler H: Metastatic malignant melanoma with an unknown primary. Surg Gynecol Obstet 1983, 156:335-340
22. Schlagenhauff B, Stroebel W, Ellwanger U, Meier F, Zimmermann C, Breuninger C, Rassner G, Barbe C: Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. Cancer 1997, 80:60-65
23. Kaufmann O, Koch S, Burghard J, Audring H, Dietel M: Tyrosinase, Melan-A, and KBA62 as markers for the immunhistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol 1998, 11:740-746
24. Zakut R, Perlis R, Eliyahu S, Yarden Y, Givol D, Lyman S, Halaban R: Kit ligand (mast cell growth factor) inhibits the growth of kit-expressing melanoma cells. Oncogene 1993, 8:2221-2229
25. Halaban R, Cheng E, Zhang Y, Moellmann G, Hanlon D, Michalak M, Setaluri M, Hebert D: Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. Proc Natl Acad Sci USA 1997, 94:6210-6215
26. Carrel S, Rimoldi D: Melanoma-associated antigens. Eur J Cancer 1993, 29A:1903-1907
27. Rossi C, Foletto A, Vecchiato S, Alessio N, Menin N, Lise M: Management of cutaneous melanoma MO: state of the art and trends. Eur J Cancer 1997, 33:2302-2312
28. Cochran A, Wen D: S-100 protein as a marker for melanocytic and other tumors. Pathology 1985, 17:340-345
29. Orchard G, Jones E: Immunocytochemistry in the diagnosis of malignant melanoma. Br J Biomed Sci 1994, 51:44-56
30. Bacchi C, Bonetti F, Pea M, Martignoni G, Gown A: HMB-45. Appl Immunhistochem 1996, 4:73-85
31. Kahn H, Marks A, Thom H, Baumal R: Role of antibody to S100 protein in diagnostic pathology. Am J Clin Pathol 1983, 79:341-347
32. Busam K, Chen Y, Old L, Stockert E, Iversen K, Copeland KA, Rosai J, Barnhill R, Jungbluth AA: Expression of Melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol 1998, 22:976-982
33. Elenitsas R, Schuchter L: The role of the pathologist in the diagnosis of melanoma. Curr Opin Oncol 1998, 10:162-169
34. Skelton H, Maceira J, Smith K, McCarthy W, Lupton G, Graham J: HMB-45 negative spindle cell malignant melanoma. Am J Dermatopathol 1997, 19:580-584
35. Gown A, Vogel A, Hoak A, Gough F, NcNutt M: Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations from melanocytes. Am J Pathol 1986, 123:195-203
36. Cohen T, Gitay-Gorey H, Sharon R, Shibuya M, Halaban R, Levi B, Neufeld G: VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem 1995, 270:1132-1136
37. Weilbaecher KN, Hershey CL, Takemoto CM. Horstmann M, Hemesath T, Tashjian A, Fisher D: Age-resolving osteopetrosis: a rat model implicating microphthalmia and the related transcription factor TFE3. J Exp Med 1998, 187:775-785
38. Herrera G, Turbat-Herrera E, Lott R: S-100 protein expression by primary, and metastatic adenocarcinomas. Am J Clin Pathol 1998, 89:168-176
39. Ackerman L: Surgical Pathology. Vol. 1. St. Louis, Mosby, 1953, p 115
40. Schmitt F, Bachhi C: S100 protein: is it useful as a tumour marker in diagnostic immunocytochemistry? Histopathology 1989, 15:281-288
41. Stefansson K, Wollmann R, Jerkovic M: S100 protein in soft-tissue tumours dervied from schwann cells and melanocytes. Am J Pathol 1982, 106:261-268
42. Guillermo A, Herrera E, Turbat-Herrera A: S100 protein expression by primary and metastatic adenocarcinomas. Am J Clin Pathol 1988, 89:168-176
43. Drier J, Swanson P, Cherwitz D, Wick M: S-100 protein immunoreactivity in poorly differentiated carcinomas: immunohistochemical comparison with malignant melanoma. Arch Pathol Lab Med 1987, 111: 447-452
44. Zarbo R, Gown A, Visscher D, Crissman J: Anomolous cytokeratin expression in malignant melanoma: one and two dimensional Western blot analysis and immunohistochemical survey of 199 melanomas. Mod Pathol 1990, 3:494-501
45. Yoneda T, Sasaki A, Mundy G: Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 1994, 32:73-84
46. Scher H, Yagoda A: Bone metastases: pathogenesis, treatment and rationale for use of resorption inhibitors. Am J Med 1987, 82:6-28
47. Littlewood-Evans A, Bilbe G, Bowler W, Farley D, Wlordski B, Kokubo T; Inaoka T, Sloane J, Evans D, Gallager J: The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 1997, 57:5386-5390
48. Kwon BS: Pigmentation genes: the tyrosinase gene family and the pmel 17 gene family. J Invest Dermatol 1993, 100:134S-140S